RxDoctor Payments Data

Rebecca Sweet, MD

Internal Medicine · Bay Minette, ALNPI 1679732408

Payments from drug & device makers

$2,220in general payments, 2019–2025

Across 133 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$410
  • Novo Nordisk$403
  • Merck$268
  • Lilly USA, LLC$240
  • Boehringer Ingelheim$160
  • AstraZeneca$85
  • plus $654 from 16 others

What the payments were for

  • Food & beverage$2,20899%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,220 in reported general payments places this provider in the 70th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$68,199
Medicare patients
150
Services billed
1,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide245$280,256
MounjaroTirzepatide167$211,889
FarxigaDapagliflozin Propanediol104$103,008
TrulicityDulaglutide74$86,218
JardianceEmpagliflozin81$79,319
JanuviaSitagliptin Phosphate92$78,488
EliquisApixaban63$73,872
MyrbetriqMirabegron66$56,329
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog98$53,001
LinzessLinaclotide28$36,065
KerendiaFinerenone39$35,897
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$26,134
GemtesaVibegron25$24,729
XareltoRivaroxaban27$21,234
VascepaIcosapent Ethyl26$17,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$240$298,107241 claims
Novo NordiskOzempic$403$280,256245 claims
AstraZenecaFarxiga, Breztri Aerosphere$85$115,840117 claims
Boehringer IngelheimJardiance, Stiolto Respimat$160$94,070100 claims
MerckJanuvia, Belsomra$268$84,594106 claims
PfizerEliquis$84$73,87263 claims
AbbVieLinzess, Ubrelvy, Qulipta, Synthroid$59$69,46898 claims
Astellas Pharma US IncMyrbetriq$40$56,32966 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$58$47,79287 claims
BayerKerendia$410$35,89739 claims
Sumitomo Pharma America, Inc.Gemtesa$16$24,72925 claims
Johnson & JohnsonXarelto$51$21,23427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Bay Minette

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →